Back to results
US 11,896,678 B2Granted
Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer
AssigneesDana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
InventorsJonathan Goldstein, Matthew Meyerson, Craig Strathdee
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for the treatment of PPARG activated cancer. For example, the present disclosure provides PPARG signaling modulators for the treatment of bladder cancer. In particular, therapeutic and/or prophylactic compositions and uses of PPARG inverse-agonists are described.
Claims15
A method of treating a subject diagnosed with a peroxisome proliferator-activated receptor gamma (PPARG) activated cancer, comprising:
- performing an assay to determine the identity of an amino acid at position 447 of PPARG and position 427 of retinoid X receptor alpha (RXRA), wherein a PPARG reference amino acid at position 447 is threonine (T) and a RXRA reference amino acid at position 427 is serine (S);
- detecting the presence of a PPARG amino acid variation relative to the PPARG reference amino acid, wherein the PPARG amino acid variation is methionine (M) and a RXRA amino acid variation relative to the RXRA reference amino acid, wherein the RXRA amino acid variation is phenylalanine (F) or tyrosine (Y);
- and
- administering a therapeutically effective amount of a PPARG signaling modulator to the subject having a PPARG T447M variation and/or a RXRA S427F/Y variation.
1 more element
Dependencies are inferred from the claim text.